Wall Street Zen Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to “Buy”

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

A number of other brokerages have also recently issued reports on REGN. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, December 29th. Truist Financial reduced their price objective on Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating on the stock in a research note on Monday, February 2nd. Cantor Fitzgerald boosted their target price on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. Royal Bank Of Canada raised their price target on Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the stock a “sector perform” rating in a research report on Monday, March 2nd. Finally, Guggenheim boosted their price objective on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $802.27.

Regeneron Pharmaceuticals Price Performance

REGN opened at $737.71 on Friday. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $77.99 billion, a P/E ratio of 17.75, a PEG ratio of 2.03 and a beta of 0.41. The stock has a 50-day moving average price of $764.67 and a 200-day moving average price of $705.95. Regeneron Pharmaceuticals has a 12-month low of $476.49 and a 12-month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The company had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.Regeneron Pharmaceuticals’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period last year, the firm posted $12.07 EPS. Equities analysts predict that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, SVP Jason Pitofsky sold 2,036 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the transaction, the senior vice president owned 4,272 shares of the company’s stock, valued at $3,325,837.44. This represents a 32.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 5,274 shares of company stock worth $4,142,738 in the last quarter. 7.02% of the stock is currently owned by company insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in REGN. WPG Advisers LLC raised its holdings in Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 25 shares in the last quarter. SHP Wealth Management purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $26,000. Salomon & Ludwin LLC purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at about $27,000. Titan Wealth CI Ltd bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth about $29,000. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new position in Regeneron Pharmaceuticals in the second quarter worth about $31,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.